Helixomer

Executive Summary

Helixomer is a preclinical-stage biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company has developed a proprietary RNA Origami (RNAO) platform that designs structurally enhanced aptamers to create nanodrugs with improved therapeutic efficacy. Helixomer is targeting difficult-to-treat indications in oncology, neurodegenerative diseases, and cardiology, areas with significant unmet medical needs. The company's approach leverages the unique properties of RNA to create stable, highly specific, and potent therapeutic agents. As a private, preclinical entity without disclosed funding rounds or valuations, Helixomer represents an early-stage opportunity in the rapidly evolving RNA therapeutics space. The RNAO platform differentiates from conventional aptamer-based therapies by enabling more complex and durable structures that could overcome typical limitations such as rapid clearance or low binding affinity.

Upcoming Catalysts (preview)

• TBDLead Program IND-Enabling Studies Initiation30% success
• TBDStrategic Partnership or Licensing Deal20% success
• TBDPublication of Preclinical Proof-of-Concept Data50% success